blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News flashes

New version of the European Patent Register - SPC information for Unitary Patents.

2024-03-06

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP3331908

EP3331908 - ANTI-ANGPTL8 ANTIBODIES AND USES THEREOF [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  14.01.2022
Database last updated on 12.07.2024
FormerThe patent has been granted
Status updated on  05.02.2021
FormerGrant of patent is intended
Status updated on  20.09.2020
FormerExamination is in progress
Status updated on  25.01.2019
FormerRequest for examination was made
Status updated on  11.05.2018
FormerThe international publication has been made
Status updated on  18.02.2017
Most recent event   Tooltip14.06.2024Lapse of the patent in a contracting state
New state(s): TR		published on 17.07.2024 [2024/29]
Applicant(s)For all designated states
Regeneron Pharmaceuticals, Inc.
777 Old Saw Mill River Road
Tarrytown, NY 10591 / US
[2018/24]
Inventor(s)01 / GUSAROVA, Viktoria
c/o Regeneron Pharmaceuticals Inc.
777 Old Saw Mill River Road
Tarrytown, New York 10591 / US
02 / GROMADA, Jesper
c/o Regeneron Pharmaceuticals Inc.
777 Old Saw Mill River Road
Tarrytown, New York 10591 / US
03 / MURPHY, Andrew J.
c/o Regeneron Pharmaceuticals Inc.
777 Old Saw Mill River Road
Tarrytown, New York 10591 / US
04 / BUCKLER, David R.
c/o Regeneron Pharmaceuticals Inc.
777 Old Saw Mill River Road
Tarrytown, New York 10591 / US
 [2018/24]
Representative(s)J A Kemp LLP
80 Turnmill Street
London EC1M 5QU / GB
[N/P]
Former [2021/10]J A Kemp LLP
14 South Square
Gray's Inn
London WC1R 5JJ / GB
Former [2018/24]J A Kemp
14 South Square
Gray's Inn
London WC1R 5JJ / GB
Application number, filing date16770103.604.08.2016
[2018/24]
WO2016US45535
Priority number, dateUS201562202366P07.08.2015         Original published format: US 201562202366 P
[2018/24]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2017027316
Date:16.02.2017
Language:EN
[2017/07]
Type: A1 Application with search report 
No.:EP3331908
Date:13.06.2018
Language:EN
The application published by WIPO in one of the EPO official languages on 16.02.2017 takes the place of the publication of the European patent application.
[2018/24]
Type: B1 Patent specification 
No.:EP3331908
Date:10.03.2021
Language:EN
[2021/10]
Search report(s)International search report - published on:EP16.02.2017
ClassificationIPC:C07K16/00, C07K16/18, C07K16/22
[2018/24]
CPC:
C07K16/22 (EP,EA,KR,US); C07K16/26 (EA,KR,US); A61K39/39575 (EA,KR,US);
A61K45/06 (EP,EA,KR,US); A61P1/18 (EP,EA); A61P3/04 (EP,EA);
A61P3/06 (EP,EA); A61P3/10 (EP,EA); A61P9/04 (EP,EA);
A61P9/10 (EP,EA); A61P9/12 (EP,EA); A61K2039/505 (EP,EA,KR,US);
A61K2039/545 (EP,EA,KR,US); A61K2039/57 (EP,EA,KR,US); C07K2317/21 (EP,EA,US);
C07K2317/33 (EP,EA,KR,US); C07K2317/34 (EP,EA,KR,US); C07K2317/76 (EP,EA,KR,US);
C07K2317/92 (EP,EA,KR,US) (-)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2018/24]
Extension statesBA02.03.2018
ME02.03.2018
Validation statesMA02.03.2018
MD02.03.2018
TitleGerman:ANTI-ANGPTL8-ANTIKÖRPER UND VERWENDUNGEN DAVON[2018/24]
English:ANTI-ANGPTL8 ANTIBODIES AND USES THEREOF[2018/24]
French:ANTICORPS ANTI-ANGPTL8 ET LEURS UTILISATIONS[2018/24]
Entry into regional phase02.03.2018National basic fee paid 
02.03.2018Designation fee(s) paid 
02.03.2018Examination fee paid 
Examination procedure02.03.2018Examination requested  [2018/24]
02.03.2018Date on which the examining division has become responsible
01.10.2018Amendment by applicant (claims and/or description)
25.01.2019Despatch of a communication from the examining division (Time limit: M04)
04.06.2019Reply to a communication from the examining division
19.08.2019Despatch of a communication from the examining division (Time limit: M04)
18.12.2019Reply to a communication from the examining division
05.03.2020Despatch of a communication from the examining division (Time limit: M06)
03.07.2020Reply to a communication from the examining division
21.09.2020Communication of intention to grant the patent
29.01.2021Fee for grant paid
29.01.2021Fee for publishing/printing paid
29.01.2021Receipt of the translation of the claim(s)
Opposition(s)13.12.2021No opposition filed within time limit [2022/07]
Fees paidRenewal fee
23.08.2018Renewal fee patent year 03
20.08.2019Renewal fee patent year 04
19.08.2020Renewal fee patent year 05
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipHU04.08.2016
AL10.03.2021
AT10.03.2021
CY10.03.2021
CZ10.03.2021
DK10.03.2021
EE10.03.2021
FI10.03.2021
HR10.03.2021
LT10.03.2021
LV10.03.2021
MC10.03.2021
MK10.03.2021
NL10.03.2021
PL10.03.2021
RO10.03.2021
RS10.03.2021
SE10.03.2021
SI10.03.2021
SK10.03.2021
SM10.03.2021
TR10.03.2021
BG10.06.2021
NO10.06.2021
GR11.06.2021
IS10.07.2021
PT12.07.2021
IE04.08.2021
LU04.08.2021
BE31.08.2021
CH31.08.2021
LI31.08.2021
[2024/29]
Former [2024/22]HU04.08.2016
AL10.03.2021
AT10.03.2021
CY10.03.2021
CZ10.03.2021
DK10.03.2021
EE10.03.2021
FI10.03.2021
HR10.03.2021
LT10.03.2021
LV10.03.2021
MC10.03.2021
MK10.03.2021
NL10.03.2021
PL10.03.2021
RO10.03.2021
RS10.03.2021
SE10.03.2021
SI10.03.2021
SK10.03.2021
SM10.03.2021
BG10.06.2021
NO10.06.2021
GR11.06.2021
IS10.07.2021
PT12.07.2021
IE04.08.2021
LU04.08.2021
BE31.08.2021
CH31.08.2021
LI31.08.2021
Former [2023/30]HU04.08.2016
AL10.03.2021
AT10.03.2021
CY10.03.2021
CZ10.03.2021
DK10.03.2021
EE10.03.2021
FI10.03.2021
HR10.03.2021
LT10.03.2021
LV10.03.2021
MC10.03.2021
NL10.03.2021
PL10.03.2021
RO10.03.2021
RS10.03.2021
SE10.03.2021
SI10.03.2021
SK10.03.2021
SM10.03.2021
BG10.06.2021
NO10.06.2021
GR11.06.2021
IS10.07.2021
PT12.07.2021
IE04.08.2021
LU04.08.2021
BE31.08.2021
CH31.08.2021
LI31.08.2021
Former [2023/29]HU04.08.2016
AL10.03.2021
AT10.03.2021
CZ10.03.2021
DK10.03.2021
EE10.03.2021
FI10.03.2021
HR10.03.2021
LT10.03.2021
LV10.03.2021
MC10.03.2021
NL10.03.2021
PL10.03.2021
RO10.03.2021
RS10.03.2021
SE10.03.2021
SI10.03.2021
SK10.03.2021
SM10.03.2021
BG10.06.2021
NO10.06.2021
GR11.06.2021
IS10.07.2021
PT12.07.2021
IE04.08.2021
LU04.08.2021
BE31.08.2021
CH31.08.2021
LI31.08.2021
Former [2022/35]AL10.03.2021
AT10.03.2021
CZ10.03.2021
DK10.03.2021
EE10.03.2021
FI10.03.2021
HR10.03.2021
LT10.03.2021
LV10.03.2021
MC10.03.2021
NL10.03.2021
PL10.03.2021
RO10.03.2021
RS10.03.2021
SE10.03.2021
SI10.03.2021
SK10.03.2021
SM10.03.2021
BG10.06.2021
NO10.06.2021
GR11.06.2021
IS10.07.2021
PT12.07.2021
IE04.08.2021
LU04.08.2021
BE31.08.2021
CH31.08.2021
LI31.08.2021
Former [2022/34]AL10.03.2021
AT10.03.2021
CZ10.03.2021
DK10.03.2021
EE10.03.2021
FI10.03.2021
HR10.03.2021
LT10.03.2021
LV10.03.2021
MC10.03.2021
NL10.03.2021
PL10.03.2021
RO10.03.2021
RS10.03.2021
SE10.03.2021
SI10.03.2021
SK10.03.2021
SM10.03.2021
BG10.06.2021
NO10.06.2021
GR11.06.2021
IS10.07.2021
PT12.07.2021
LU04.08.2021
BE31.08.2021
CH31.08.2021
LI31.08.2021
Former [2022/23]AL10.03.2021
AT10.03.2021
CZ10.03.2021
DK10.03.2021
EE10.03.2021
FI10.03.2021
HR10.03.2021
LT10.03.2021
LV10.03.2021
MC10.03.2021
NL10.03.2021
PL10.03.2021
RO10.03.2021
RS10.03.2021
SE10.03.2021
SI10.03.2021
SK10.03.2021
SM10.03.2021
BG10.06.2021
NO10.06.2021
GR11.06.2021
IS10.07.2021
PT12.07.2021
LU04.08.2021
CH31.08.2021
LI31.08.2021
Former [2022/21]AL10.03.2021
AT10.03.2021
CZ10.03.2021
DK10.03.2021
EE10.03.2021
FI10.03.2021
HR10.03.2021
LT10.03.2021
LV10.03.2021
MC10.03.2021
NL10.03.2021
PL10.03.2021
RO10.03.2021
RS10.03.2021
SE10.03.2021
SI10.03.2021
SK10.03.2021
SM10.03.2021
BG10.06.2021
NO10.06.2021
GR11.06.2021
PT12.07.2021
CH31.08.2021
LI31.08.2021
Former [2022/18]AL10.03.2021
AT10.03.2021
CZ10.03.2021
DK10.03.2021
EE10.03.2021
FI10.03.2021
HR10.03.2021
LT10.03.2021
LV10.03.2021
MC10.03.2021
NL10.03.2021
PL10.03.2021
RO10.03.2021
RS10.03.2021
SE10.03.2021
SI10.03.2021
SK10.03.2021
SM10.03.2021
BG10.06.2021
NO10.06.2021
GR11.06.2021
PT12.07.2021
Former [2022/13]AL10.03.2021
AT10.03.2021
CZ10.03.2021
DK10.03.2021
EE10.03.2021
FI10.03.2021
HR10.03.2021
LT10.03.2021
LV10.03.2021
NL10.03.2021
PL10.03.2021
RO10.03.2021
RS10.03.2021
SE10.03.2021
SI10.03.2021
SK10.03.2021
SM10.03.2021
BG10.06.2021
NO10.06.2021
GR11.06.2021
PT12.07.2021
Former [2022/10]AL10.03.2021
AT10.03.2021
CZ10.03.2021
DK10.03.2021
EE10.03.2021
FI10.03.2021
HR10.03.2021
LT10.03.2021
LV10.03.2021
NL10.03.2021
PL10.03.2021
RO10.03.2021
RS10.03.2021
SE10.03.2021
SK10.03.2021
SM10.03.2021
BG10.06.2021
NO10.06.2021
GR11.06.2021
PT12.07.2021
Former [2022/08]AL10.03.2021
AT10.03.2021
CZ10.03.2021
DK10.03.2021
EE10.03.2021
FI10.03.2021
HR10.03.2021
LT10.03.2021
LV10.03.2021
NL10.03.2021
PL10.03.2021
RO10.03.2021
RS10.03.2021
SE10.03.2021
SK10.03.2021
SM10.03.2021
BG10.06.2021
NO10.06.2021
GR11.06.2021
IS10.07.2021
PT12.07.2021
Former [2022/07]AL10.03.2021
AT10.03.2021
CZ10.03.2021
EE10.03.2021
FI10.03.2021
HR10.03.2021
LT10.03.2021
LV10.03.2021
NL10.03.2021
PL10.03.2021
RO10.03.2021
RS10.03.2021
SE10.03.2021
SK10.03.2021
SM10.03.2021
BG10.06.2021
NO10.06.2021
GR11.06.2021
IS10.07.2021
PT12.07.2021
Former [2021/52]AT10.03.2021
CZ10.03.2021
EE10.03.2021
FI10.03.2021
HR10.03.2021
LT10.03.2021
LV10.03.2021
NL10.03.2021
PL10.03.2021
RO10.03.2021
RS10.03.2021
SE10.03.2021
SK10.03.2021
SM10.03.2021
BG10.06.2021
NO10.06.2021
GR11.06.2021
IS10.07.2021
PT12.07.2021
Former [2021/51]AT10.03.2021
CZ10.03.2021
EE10.03.2021
FI10.03.2021
HR10.03.2021
LT10.03.2021
LV10.03.2021
NL10.03.2021
RO10.03.2021
RS10.03.2021
SE10.03.2021
SK10.03.2021
SM10.03.2021
BG10.06.2021
NO10.06.2021
GR11.06.2021
IS10.07.2021
PT12.07.2021
Former [2021/50]AT10.03.2021
CZ10.03.2021
EE10.03.2021
FI10.03.2021
HR10.03.2021
LT10.03.2021
LV10.03.2021
NL10.03.2021
RO10.03.2021
RS10.03.2021
SE10.03.2021
SK10.03.2021
SM10.03.2021
BG10.06.2021
NO10.06.2021
GR11.06.2021
PT12.07.2021
Former [2021/48]AT10.03.2021
CZ10.03.2021
EE10.03.2021
FI10.03.2021
HR10.03.2021
LT10.03.2021
LV10.03.2021
NL10.03.2021
RS10.03.2021
SE10.03.2021
SM10.03.2021
BG10.06.2021
NO10.06.2021
GR11.06.2021
Former [2021/46]AT10.03.2021
FI10.03.2021
HR10.03.2021
LT10.03.2021
LV10.03.2021
NL10.03.2021
RS10.03.2021
SE10.03.2021
SM10.03.2021
BG10.06.2021
NO10.06.2021
GR11.06.2021
Former [2021/43]FI10.03.2021
HR10.03.2021
LT10.03.2021
LV10.03.2021
NL10.03.2021
RS10.03.2021
SE10.03.2021
BG10.06.2021
NO10.06.2021
GR11.06.2021
Former [2021/38]FI10.03.2021
HR10.03.2021
LT10.03.2021
LV10.03.2021
RS10.03.2021
SE10.03.2021
BG10.06.2021
NO10.06.2021
GR11.06.2021
Former [2021/37]FI10.03.2021
HR10.03.2021
LT10.03.2021
LV10.03.2021
RS10.03.2021
BG10.06.2021
NO10.06.2021
GR11.06.2021
Former [2021/36]FI10.03.2021
HR10.03.2021
LT10.03.2021
BG10.06.2021
NO10.06.2021
GR11.06.2021
Former [2021/35]FI10.03.2021
HR10.03.2021
LT10.03.2021
NO10.06.2021
Former [2021/33]FI10.03.2021
LT10.03.2021
NO10.06.2021
Cited inInternational search[XDY]  - Zhang Ren, "OR13-6: A Monoclonal Neutralizing Antibody Against Lipasin (Angptl8), a Novel Lipid Regulator, Reduces Serum Triglycerides in Mice By Enhancing Lipoprotein Lipase-Mediated Triglyceride Clearance", CV Risk - Drugs, Sex, and Rock and Roll, doi:10.1210/endo-meetings.2015.DGM.3.OR13-6, (20150306), ENDOCRINE SOCIETY'S 97TH ANNUAL MEETING AND EXPO, March 5-8, 2015 - SAN DIEGO, URL: http://press.endocrine.org/doi/10.1210/endo-meetings.2015.DGM.3.OR13-6, (20161108), XP002763964 [XD] 1-4,6-19 * the whole document * [Y] 5

DOI:   http://dx.doi.org/10.1210/endo-meetings.2015.DGM.3.OR13-6
 [XY]  - Anonymous, "Product Data Sheet - Purified anti-Betatrophin (ANGPTL8)", (20140725), BioLegend, URL: http://www.biolegend.com/pop_pdf.php?id=10113, (20161108), XP002763965 [X] 1-4,6-19 * the whole document * [Y] 5
ExaminationUS2011150901
 US8545847
by applicantUS6596541
 WO2005103081
 US2008261236
 US7598227
 US7750141
 US2011002845
 US2011150901
 US2011159015
 WO2012174178
 US8530439
 US8545847
    - FU, Z., BIOCHEM. BIOPHYS. RES. COMMUN, (2013), vol. 430, pages 1126 - 1131
    - QUAGLIARINI, F., PROC. NATL. ACAD. SCI. USA, (2012), vol. 109, no. 48, pages 19751 - 19756
    - WANG, Y., PROC. NATL. ACAD. SCI. USA, (2013), vol. 110, pages 16109 - 16114
    - ZHANG, R., BIOCHEM. BIOPHYS. RES. COMMUN., (2012), vol. 424, pages 786 - 792
    - YI, P., CELL, (2013), vol. 153, pages 747 - 758
    - GUSAROVA, V., CELL, (2014), vol. 159, pages 691 - 696
    - REDDY ET AL., J. IMMUNOL., (2000), vol. 164, pages 1925 - 1933
    - AL-LAZIKANI ET AL., J. MOL. BIOL., (1997), vol. 273, pages 927 - 948
    - MARTIN ET AL., PROC. NATL. ACAD. SCI. USA, (1989), vol. 86, pages 9268 - 9272
    - SHIELD ET AL., JBC, (2002), vol. 277, page 26733
    - TAYLOR ET AL., NUCL. ACIDS RES., (1992), vol. 20, pages 6287 - 6295
    - PEARSON, METHODS MOL. BIOL, (1994), vol. 24, pages 307 - 331
    - GONNET ET AL., SCIENCE, (1992), vol. 256, pages 1443 - 1445
    - ALTSCHUL ET AL., J. MOL. BIOL., (1990), vol. 215, pages 403 - 410
    - NUCLEIC ACIDS RES., (1997), vol. 25, pages 3389 - 3402
    - HARLOW; LANE, scanning mutational analysis, peptide blots analysis, COLD SPRING HARBOR PRESS
    - REINEKE, METHODS MOL BIOL, (2004), vol. 248, pages 443 - 463
    - TOMER, PROTEIN SCIENCE, (2000), vol. 9, pages 487 - 496
    - EHRING, ANALYTICAL BIOCHEMISTRY, (1999), vol. 267, no. 2, pages 252 - 259
    - ENGEN; SMITH, ANAL. CHEM., (2001), vol. 73, pages 256A - 265A
    - JUNGHANS ET AL., CANCER RES., (1990), vol. 50, pages 1495 - 1502
    - TUTT ET AL., J. IMMUNOL., (1991), vol. 147, pages 60 - 69
    - KUFER ET AL., TRENDS BIOTECHNOL., (2004), vol. 22, pages 238 - 244
    - KAZANE ET AL., J. AM. CHEM. SOC.
    - Remington's Pharmaceutical Sciences, MACK PUBLISHING COMPANY
    - POWELL ET AL., "Compendium of excipients for parenteral formulations", J PHARM SCI TECHNOL, (1998), vol. 52, pages 238 - 311, XP009119027
    - MORDENTI ET AL., PHARMACEUT. RES., (1991), vol. 8, page 1351
    - WU ET AL., J. BIOL. CHEM., (1987), vol. 262, pages 4429 - 4432
    - SEFTON, CRC CRIT. REF. BIOMED. ENG., (1987), vol. 14, page 201
    - GOODSON, MEDICAL APPLICATIONS OF CONTROLLED RELEASE, (1984), vol. 2, pages 115 - 138
    - LANGER, SCIENCE, (1990), vol. 249, pages 1527 - 1533
    - LEE ET AL., JBC, (2009), vol. 284, pages 13735 - 13745
    - DESAI ET AL., PNAS, (2007), vol. 104, pages 11766 - 11771
    - POSTHUMUS ET AL., J VIROL, (1990), vol. 64, pages 3304 - 3309
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.